DUBLIN--(BUSINESS WIRE)--The "Worldwide Organ on a Chip (OOC) Market [by Segments (Devices, Services); by Types (Lung, Heart, Liver, Intestine, Kidney, Human, Placenta, Gut, Nerve, Others); by Regions (North America, Europe, APAC, CALA, MEA)]: Sizes and Forecasts (2018-2023)" report has been added to ResearchAndMarkets.com's offering.
Drug and pharmaceutical companies lose billions of dollars due to high drug failure rates in clinical trials, largely due to the current limitations of using animal models and static cell culture systems. Coupled with this is the fact that the in-vitro modeling and therapy development for many diseases is not accurate. This creates a direct need for clinical modeling that is physiologically relevant to human organs and at the same time intuitively integrating human-derived cells with sensor-driven OOC systems.
However, complexities of organ functions aren't easy to model. Creating an OOC system is a complicated process with multiple hurdles to cross. Firstly, there is a major need to accurately reproduce the architectural complexity of organs and tissues in vitro. Then, there is a bigger need to accurately link them in the correct format for the connected systems to recapitulate tissue-organ interactions. Solving this is set to be industry's key priority. OOCs provide tremendous potential if commercialization is aided by collaborative efforts across the value-chain and ecosystem. Regulators, medical professionals, scientists, technicians, and organizations need to collaborate to usher in the future of medicine through OOCs.
Challenges aside, OOCs offer a possible opportunity to replace current animal based testing and assessments over time. However, it is unlikely that OOCs are comprehensive enough to make that change during the forecast period due to the traditional regulatory requirements and complexities of organ functions. The current forecast period is the earliest phase of market adoption for organ-on-a-chip players. The next decade is a favorable period for upward trend in regulation, ratification, and adoption. The use of OOCs, as a viable alternative to traditional clinical lab options, in an improving regulatory environment and increasing marketplace acceptance, promises to lay the foundation of the future of accurate medicine.
OOCs are a key piece in the future of personalized medicine, and collaborative efforts across the ecosystem are key to ensure widespread adoption. The market opportunity for Organ-on-a-Chip across the globe is considerable overall.
Companies Featured
- 4Dcell
- AxoSim Techologies LLC
- CN Bio Innovations
- Cherry Biotech SAS
- Elvesys
- Emulate
- Hepregen
- Hesperos
- HREL
- Insphero
- Micronit Microtechnologies B.V.
- Mimetas
- Nortis
- Organovo Holdings Inc.
- Sophion Bioscience
- Tara Biosystems
- thinXXS Microtechnology AG
- TissUse
Key Topics Covered
1 Organ-on-a-Chip: Research Overview and Summary
2 Organ-on-a-Chip: Market Size and Forecast by Segments
3 Organ-on-a-Chip: Market Size and Forecast by Types
4 Organ-on-a-Chip: Market Size and Forecasts by Regions
5 Organ-on-a-Chip: Extended Market Forecasts (2018-2027)
For more information about this report visit https://www.researchandmarkets.com/research/7h9qw2/global?w=4
